ClinicalTrialsFinder
RecruitingNCT05498675

Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study

Sponsor

Beijing Friendship Hospital

Enrollment

180 participants

Start Date

Sep 1, 2021

Study Type

OBSERVATIONAL

Conditions

ObesityHypertensionSacubitril/Valsartan

Summary

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is looking at how a blood pressure medication called sacubitril/valsartan (brand name Entresto) affects heart function in people with high blood pressure, and whether the effect differs based on body weight (BMI). **You may be eligible if...** - You have been diagnosed with essential (primary) high blood pressure - You are between 18 and 70 years old - You are able to provide written consent **You may NOT be eligible if...** - Your high blood pressure is caused by another condition (secondary hypertension), unless it's from sleep apnea - You had a heart attack, stroke, heart failure, or heart procedure in the last 6 months - You have a serious illness such as autoimmune disease, cancer, or severe liver or lung disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSacubitril / Valsartan Oral Tablet [Entresto]

There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.

DRUGACEI/ARB

There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.

Locations(1)

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05498675

Related Trials

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT074073481 location

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

NCT072258161 location

A Study of LY3971297 in Healthy Participants

NCT061482727 locations

Evaluation of the Care Pathway Offered by the "Chronic Disease Unit" to Obese Patients

NCT065382201 location

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

NCT0749788023 locations